Boston's SPECT (single photon emission computed tomography) contrast agent shows up Parkinson's
This article was originally published in Clinica
Executive Summary
A Phase III clinical trial has shown that the imaging agent, Altropane, is capable of distinguishing Parkinson's disease from other brain-related movement disorders.